Is <i>Fusobacterium nucleatum</i> the key mediator between oral infections and systemic diseases? Mechanistic insights and therapeutic implications.
Fusobacterium nucleatum is identified as a key player in the link between oral infections and systemic diseases, with potential therapeutic strategies under exploration.
Where it sits
this study against the rest of the argireline corpusSummary and findings
This review discusses the role of Fusobacterium nucleatum in linking oral infections to systemic diseases. It highlights various mechanisms through which this bacterium contributes to conditions like colorectal cancer and cardiovascular diseases. The review also explores potential therapeutic strategies targeting these mechanisms.
Abstract
<i>Fusobacterium nucleatum</i> has emerged as a pathobiont that associates oral dysbiosis with systemic diseases through coaggregation, hematogenous dissemination, and immune modulation. This review provides molecular insights through which they are involved in systemic diseases such as colorectal cancer, adverse pregnancy outcomes, cardiovascular diseases, neurodegenerative disorders, and diabetes mellitus. Key virulence factors include the adhesins of FadA, Fap2, and RadD, lipopolysaccharides, and outer membrane vesicles, which mediate epithelial invasion and endothelial permeafbility and facilitate immune suppression through TLR4-NF-κB, β-catenin/Wnt, and MAPK signaling pathways. These interactions result in impaired tissue homeostasis, propagate chronic inflammation, and promote oncogenic and metabolic modulation. Systemic pleiotropy of <i>F. nucleatum</i> is further substantiated by its involvement in chemoresistance, placental dysfunction, vascular inflammation, and neuronal injury, substantiating its systemic pleiotropy. Emerging therapeutic strategies, such as blocking adhesins, neutralizing outer membrane vesicles, microbiome manipulation, and using CRISPR-based clearance, provide precision techniques for mitigating diseases. Therefore, this review identifies <i>F. nucleatum</i> as the primary microbial mediator of oral-systemic pathology and its translational significance in the development of targeted antimicrobial and host-directed therapies.
Background
This review addresses the connection between oral dysbiosis and systemic diseases, focusing on Fusobacterium nucleatum as a significant pathobiont. Previous studies have established associations between oral health and various systemic conditions, but the specific mechanisms remain under investigation. Understanding these pathways is crucial for developing targeted interventions.
Methods
The review synthesizes existing literature on Fusobacterium nucleatum's role in systemic diseases, discussing its virulence factors and mechanisms of action. It does not present original research data but rather compiles findings from various studies to elucidate the bacterium's systemic effects.
Results
Not reported in abstract.
Interpretation
The findings suggest that Fusobacterium nucleatum plays a multifaceted role in systemic diseases, corroborating previous literature on oral-systemic health connections. However, the clinical significance of these associations requires further investigation, particularly regarding the impact of potential therapeutic strategies. Limitations include the lack of original data and reliance on existing studies, which may vary in quality and methodology.
Key findings
- Fusobacterium nucleatum is associated with systemic diseases through coaggregation and immune modulation.
- Key virulence factors include FadA, Fap2, RadD, lipopolysaccharides, and outer membrane vesicles.
- These interactions result in impaired tissue homeostasis and propagate chronic inflammation.
- Emerging therapeutic strategies include blocking adhesins and microbiome manipulation.
Limitations
- Not a primary research study, but a review of existing literature.
- Lacks original data to support claims.
- Potential variability in the quality of referenced studies.